News
IFM will be eligible for potential milestone payments in aggregate value of up to $835 million, giving Novartis full rights to its STING antagonist program Announcement represents the outcome of a ...
IFM will be eligible for potential milestone payments in aggregate value of up to $835 million, giving Novartis full rights to its STING antagonist program Announcement represents the outcome of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback